We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
+1.1%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$800M
AUM Growth
-$196M
Cap. Flow
-$191M
Cap. Flow %
-23.93%
Top 10 Hldgs %
45.64%
Holding
76
New
18
Increased
11
Reduced
22
Closed
17

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$44.5M
2
TMO icon
Thermo Fisher Scientific
TMO
+$28.7M
3
A icon
Agilent Technologies
A
+$25.7M
4
AMGN icon
Amgen
AMGN
+$18.3M
5
DXCM icon
DexCom
DXCM
+$15.1M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$73M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$47.1M
3
NTRA icon
Natera
NTRA
+$39.7M
4
BSX icon
Boston Scientific
BSX
+$34.1M
5
RVNC
Revance Therapeutics, Inc.
RVNC
+$27.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVNC
51
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.74M 0.22%
64,590
-1,353,498
-95% -$27.5M
ISEE
52
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.53M 0.19%
+85,230
New +$1.12M
CYPH
53
Cypherpunk Technologies Inc
CYPH
$73.3M
$939K 0.12%
106,669
– –
IMA
54
ImageneBio Inc
IMA
$64.6M
$781K 0.1%
18,340
– –
EQRXW
55
DELISTED
EQRx, Inc. Warrant
EQRXW
$29K ﹤0.01%
35,239
-64,759
-65% -$62.6K
LGV.WS
56
DELISTED
Longview Acquisition Corp. II Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
LGV.WS
$10K ﹤0.01%
149,999
-277,179
-65% -$36.8K
EUCRW
57
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$2K ﹤0.01%
78,059
– –
MSACW
58
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$1K ﹤0.01%
29,776
-52,887
-64% -$10.1K
ALGN icon
59
CALL
Align Technology
ALGN
$12.3B
– –
-10,000
Closed -$2.37M
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-239,820
Closed -$2.54M
BSX icon
61
CALL
Boston Scientific
BSX
$71.5B
– –
-500,000
Closed -$18.6M
COO icon
62
Cooper Companies
COO
$14.5B
– –
-123,080
Closed -$9.63M
LKFT
63
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
– –
-55,280
Closed -$3.08M
IBB icon
64
iShares Biotechnology ETF
IBB
$9.77B
– –
-53,940
Closed -$6.34M
ISRG icon
65
Intuitive Surgical
ISRG
$134B
– –
-72,490
Closed -$14.5M
PODD icon
66
Insulet
PODD
$9.79B
– –
-7,150
Closed -$1.56M
QTRX icon
67
Quanterix
QTRX
$190M
– –
-201,560
Closed -$3.26M
RAPT
68
DELISTED
RAPT Therapeutics
RAPT
– –
-27,146
Closed -$3.96M
TEVA icon
69
Teva Pharmaceuticals
TEVA
$41.2B
– –
-499,640
Closed -$3.76M
UHS icon
70
Universal Health Services
UHS
$10.5B
– –
-134,040
Closed -$13.5M
XLV icon
71
State Street Health Care Select Sector SPDR ETF
XLV
$42.7B
– –
-34,610
Closed -$4.44M
ZBH icon
72
Zimmer Biomet
ZBH
$18.4B
– –
-72,020
Closed -$7.57M
ITCI
73
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-27,070
Closed -$1.54M
OHPAW
74
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
$0 ﹤0.01%
50,105
-87,200
-64% -$8.23K
CCXI
75
CALL
DELISTED
ChemoCentryx, Inc.
CCXI
– –
-100,000
Closed -$2.48M
1 2
3
4

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q3 2022 Portfolio in Review

As of Q3 2022, HealthCor Management held 76 positions worth $800M, down 20% from $995M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

HealthCor Management withdrew a net $191M in Q3 2022, closing 17 positions and reducing 22 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $27.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 94% a quarter earlier, followed by Financials.

Against the trend, HealthCor Management opened a new position in AbbVie worth $41.6M.

  • HealthCor Management's largest Q3 2022 buy was AbbVie: 310,250 shares worth $41.6M.
  • HealthCor Management added most to Agilent Technologies in Q3 2022, an estimated $25.7M increase.
  • HealthCor Management's biggest Q3 2022 reduction was Biogen, cutting an estimated $73M.
  • HealthCor Management fully exited ChemoCentryx, Inc. in Q3 2022, selling an estimated $27.2M.
  • HealthCor Management's ten largest holdings make up 46% of its $800M portfolio in Q3 2022.
  • HealthCor Management opened 18 new positions and closed 17 in Q3 2022.
  • HealthCor Management's portfolio value fell 20% quarter-over-quarter to $800M.

Based on HealthCor Management's 13F filing for Q3 2022, filed 14 Nov 2022.